Home » Topics » Neurology/psychiatric, BioWorld Science

Neurology/psychiatric, BioWorld Science
RSS

Synapton phase III trials concluded

Aug. 30, 1996

Prednisone suppresses acute phase in AD patients

Aug. 30, 1996

Botulinum toxin effective in treating writer's cramp

Aug. 30, 1996

Botulinum toxin effective in reducing upper limb spasticity

Aug. 30, 1996

Roche files for approval of Tasmar

Aug. 30, 1996

Tegretol-XR launched in U.S.

Aug. 30, 1996

CGP-25454 tested in healthy volunteers

Aug. 30, 1996

Correlation established between serum PLA2 activity and schizophrenia symptoms

Aug. 30, 1996

Potential antipsychotic described by Parke-Davis

Aug. 30, 1996

Famotidine tested in schizophrenic patients

Aug. 30, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...